Canton Strategic (CNTN) vs Veraxa Biotech (VRXA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Canton Strategic (CNTN) has outperformed Veraxa Biotech (VRXA) over the past year, losing 25.2% versus a loss of 88.5%. Canton Strategic is the larger company by market cap ($166.1 million vs $159.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNTN | VRXA |
|---|---|---|
| Share price | $2.09 | $1.13 |
| Market cap | $166.14M | $159.79M |
| 1-day change | -7.73% | -5.74% |
| YTD return | -25.41% | -88.75% |
| 1-year return | -25.17% | -88.53% |
| EPS (TTM) | $-0.10 | $-0.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.89 | $27.36 |
| 52-week low | $1.75 | $1.04 |
| Distance from 52-week high | -69.74% | -95.87% |
| Average volume | 751.76K | 274.75K |
| Shares outstanding | 79.68M | 141.41M |
| Employees | 12 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CNTN has outperformed VRXA by 63.4 percentage points over the past year.
About Canton Strategic
CNTN stock →Canton Strategic Holdings, Inc. engages in the institutional blockchain adoption and digitization of financial markets in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
About Veraxa Biotech
VRXA stock →VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation.
Health Care · Biotechnology: Pharmaceutical Preparations
CNTN vs VRXA FAQ
Which is bigger, Canton Strategic or Veraxa Biotech?
Canton Strategic (CNTN) is larger, with a market capitalization of $166.14M compared with $159.79M for Veraxa Biotech (VRXA).
Which stock has performed better over the past year, CNTN or VRXA?
CNTN returned -25.17% over the past 12 months, compared with -88.53% for VRXA (price return, excluding dividends). Past performance does not predict future results.
Are Canton Strategic and Veraxa Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.